hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06287528 id: 23-307 briefTitle: A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) overallStatus: RECRUITING date: 2024-02-23 date: 2028-02-23 date: 2028-02-23 date: 2024-03-01 date: 2024-04-03 name: Memorial Sloan Kettering Cancer Center class: OTHER briefSummary: Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks. conditions: Philadelphia-Negative ALL conditions: Philadelphia-Positive ALL conditions: Relapsed ALL, Adult conditions: Refractory Acute Lymphoblastic Leukemia conditions: Refractory Acute Lymphoblastic Leukemia (ALL) conditions: Refractory Acute Lymphoid Leukemia in Relapse studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: 19-28z/IL-18 CAR T cells measure: Toxicity as determined by CTCAE, version 5.0 sex: ALL minimumAge: 17 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) status: RECRUITING city: Basking Ridge state: New Jersey zip: 07920 country: United States name: Jae Park, MD role: CONTACT phone: 646-608-3743 lat: 40.70621 lon: -74.54932 facility: Memorial Sloan Kettering Monmouth (Limited Protocol Activities) status: RECRUITING city: Middletown state: New Jersey zip: 07748 country: United States name: Jae Park, MD role: CONTACT phone: 646-608-3743 lat: 40.39652 lon: -74.09211 facility: Memorial Sloan Kettering Bergen (Limited Protocol Activities) status: RECRUITING city: Montvale state: New Jersey zip: 07645 country: United States name: Jae Park, MD role: CONTACT phone: 646-608-3743 lat: 41.04676 lon: -74.02292 facility: Memorial Sloan Kettering Cancer Suffolk-Commack (Limited Protocol Activities) status: RECRUITING city: Commack state: New York zip: 11725 country: United States name: Jae Park, MD role: CONTACT phone: 646-608-3743 lat: 40.84288 lon: -73.29289 facility: Memorial Sloan Kettering Westchester (Limited Protocol Activities) status: RECRUITING city: Harrison state: New York zip: 10604 country: United States name: Jae Park, MD role: CONTACT phone: 646-608-3743 lat: 40.96899 lon: -73.71263 facility: Memorial Sloan Kettering Cancer Center (All Protocol Activities) status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Jae Park, MD role: CONTACT phone: 646-608-3743 lat: 40.71427 lon: -74.00597 facility: Memorial Sloan Kettering Nassau (Limited Protocol Activities) status: RECRUITING city: Uniondale state: New York zip: 11553 country: United States name: Jae Park, MD role: CONTACT phone: 646-608-3743 lat: 40.70038 lon: -73.59291 hasResults: False
nctId: NCT06287515 id: 2023-0940 id: NCI-2024-01986 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2025-07-01 date: 2027-07-01 date: 2024-03-01 date: 2024-03-04 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To learn if hypophysectomy (treatment of the pituitary gland) using a type of radiation treatment called stereotactic radiosurgery (SRS) can help to relieve cancer-related pain. conditions: Hypophysectomy studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: Stereotactic Radiosurgery measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Chenyang Wang, MD role: CONTACT phone: 832-710-1570 email: cwang23@mdanderson.org name: Chenyang Wang, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06287502 id: KHRehab_LeungHC_2 briefTitle: Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis overallStatus: ACTIVE_NOT_RECRUITING date: 2022-09-09 date: 2024-04-30 date: 2024-06-30 date: 2024-03-01 date: 2024-03-04 name: Kowloon Hospital, Hong Kong class: OTHER briefSummary: This is a prospective parallel group, double-blinded randomized controlled trial. Subjects are randomized into two groups - the intervention group and waitlist control group. Subjects received resistance, aerobic, flexibility and balance exercise training; and nutritional supplement containing β-hydroxy β-methylbutyrate (HMB). The intervention group would first receive the intervention during the 12-week study period. Meanwhile, the waitlist control group would receive 12 weeks of conventional care. After the study period, they would receive the same intervention. conditions: Sarcopenia conditions: Osteoporosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: β-hydroxy β-methylbutyrate (HMB) name: Resistance, aerobic, flexibility and balance exercise training measure: Grip strength measure: Body weight measure: Body mass index measure: Appendicular skeletal muscle mass index measure: 6-metre walk test measure: 5-time chair stand test measure: Short Physical Performance Battery (SPPB) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Kowloon Hospital city: Kowloon country: Hong Kong lat: 22.31667 lon: 114.18333 hasResults: False
nctId: NCT06287489 id: No.:2023-08-010ACF briefTitle: Effects of Mediterranean Diet on Subjective Cognitive Decline overallStatus: RECRUITING date: 2023-10-26 date: 2025-10-31 date: 2025-12-31 date: 2024-03-01 date: 2024-03-01 name: Chih-Ping Chung class: OTHER_GOV name: National Yang Ming Chiao Tung University briefSummary: Research Questions:
Conduct a cross-over randomized controlled trial to investigate the effects of a three-month Mediterranean diet on the physical and cognitive functions of older adults with subjective cognitive decline (SCD) in the community. Utilize brain MRI and circulatory biomarkers measurements to elucidate the underlying mechanisms. conditions: Subjective Cognitive Decline studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Mediterranean diet phase X regular diet phase primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Mediterranean diet name: Regular diet measure: Cognitive functional change measure: Physical function 1 - gait speed change measure: Physical function 2 - handgrip strength change measure: Physical function 3 - stand from chair speed change measure: Brain MRI structural change - total and regional voxel-based brain parenchymal features change measure: Brain MRI functional change - total and regional voxel-based brain functional features change measure: Brain MRI neurovascular lesion change - small vessel disease markers measure: Brain MRI neurovascular structural change - microvascular density measure: AD circulatory biomarkers sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Veterans General Hospital status: RECRUITING city: Taipei zip: 11217 country: Taiwan name: Chih-Ping Chung, MD PhD role: CONTACT phone: +886-2-918155976 email: pin324pin324@gmail.com lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06287476 id: H-23043870 briefTitle: Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA) overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-03-15 date: 2025-03-15 date: 2024-03-01 date: 2024-03-01 name: Rigshospitalet, Denmark class: OTHER briefSummary: It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea. The aim of this study is to investigate whether individuals with COPD exhibit an abnormal increase in alveolar-capillary breaching during exertion, as indicated by an increase alveolar-capillary permeability with a concomitantly exacerbated increase in lung tissue mass. conditions: Chronic Obstructive Pulmonary Disease studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 32 type: ESTIMATED name: Acute exercise bout on visit 2 and 3 measure: Rest-to-exercise pulmonary DTPA clearance change after exercise in COPD vs. controls measure: Pulmonary DTPA clearance at rest in COPD vs. controls measure: Pulmonary DTPA clearance after exercise in COPD vs. controls measure: Rest-to-exercise change in lung tissue mass in COPD vs. controls measure: Lung tissue mass at rest in COPD vs. controls measure: Lung tissue mass after exercise in COPD vs. controls measure: Rest-to-exercise pulmonary DTPA clearance and lung tissue mass change according to GOLD measure: Supine pulmonary capillary blood volume after exercise in COPD vs. controls measure: Supine cardiac output after exercise in COPD vs. controls measure: Supine pulmonary capillary blood volume at rest in COPD vs. controls measure: Supine cardiac output at rest in COPD vs. controls measure: Supine pulmonary diffusing capacity to nitric oxide (DLNO) after exercise in COPD vs. controls measure: Supine haemoglobin-corrected pulmonary diffusing capacity to carbon monoxide (DLCOc) after exercise in COPD vs. controls measure: Supine alveolar-capillary membrane diffusing capacity (DM) after exercise in COPD vs. controls measure: Supine pulmonary diffusing capacity to nitric oxide (DLNO) at rest in COPD vs. controls measure: Supine haemoglobin-corrected pulmonary diffusing capacity to carbon monoxide (DLCOc) at rest in COPD vs. controls measure: Supine alveolar-capillary membrane diffusing capacity (DM) at rest in COPD vs. controls sex: ALL minimumAge: 45 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center For Physical Activity Research, Rigshospitalet city: Copenhagen country: Denmark lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06287463 id: DCC-3084-01-001 briefTitle: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-08 date: 2027-08 date: 2024-03-01 date: 2024-04-29 name: Deciphera Pharmaceuticals LLC class: INDUSTRY briefSummary: This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). conditions: Advanced Solid Tumor conditions: RAF Mutation conditions: RAS Mutation conditions: NF1 Mutation conditions: Non-Small Cell Lung Cancer conditions: Pancreatic Ductal Adenocarcinoma conditions: Melanoma conditions: BRAF Gene Mutation conditions: CRAF Gene Mutation studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 140 type: ESTIMATED name: DCC-3084 measure: Number of Participants with Dose-limiting Toxicities (DLTs) (ModA Part 1) measure: Objective Response Rate (ORR) (ModA Part 2) measure: ORR (ModA Part 1) measure: Progression-Free Survival (PFS) (ModA Part 1 and 2) measure: Overall Survival (OS) (ModA Part 1 and 2) measure: Pharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax) (ModA Part 1 and 2) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NEXT Oncology city: San Antonio state: Texas zip: 78229 country: United States name: Ildefonso Ismael Rodriguez Rivera, MD role: PRINCIPAL_INVESTIGATOR lat: 29.42412 lon: -98.49363 facility: NEXT Oncology Virginia city: Fairfax state: Virginia zip: 22031 country: United States name: Alexander Spira, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 38.84622 lon: -77.30637 hasResults: False
nctId: NCT06287450 id: IN006001 briefTitle: A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-04 date: 2026-10 date: 2024-03-01 date: 2024-03-01 name: Shenzhen Shenxin Biotechnology Co., Ltd class: INDUSTRY briefSummary: The study will evaluate the safety, tolerability, and immunogenicity of a single injection of up to 4 dose levels of IN006 in younger adults and 3 dose levels of IN006 in older adults; of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults. conditions: Respiratory Syncytial Virus Infections studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: Bivalent RSV Vaccine (IN006) name: Placebo measure: Percentage of Participants With Solicited Local and Systemic Adverse Reactions Through 14 Days After Initial Vaccination measure: Percentage of Participants With Unsolicited Adverse Events (AEs) Through 28 Days After Initial Vaccination measure: Percentage of Participants With Any Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Study Discontinuation Through 12 Months After Initial Vaccination measure: Percentage of Participants With Any Medically Attended AEs (MAAEs) Through 6 Months After Initial Vaccination measure: Geometric Mean Titer (GMT) for Neutralizing Antibodies Against RSV A and RSV B (Via Neutralization Assay) measure: Geometric Mean Fold Rise (GMFR) for Neutralizing Antibodies Against RSV A and RSV B (Via Neutralization Assay) measure: Vaccine Response Rate for Neutralizing Antibodies Against RSV A and RSV B (Via Neutralization Assay) measure: GMC for Pre-F Specific Binding Antibodies Against RSV A and RSV B (Via Enzyme Immunoassay [EIA]) measure: GMFR for Pre-F Specific Binding Antibodies Against RSV A and RSV B (Via Enzyme Immunoassay [EIA]) measure: Vaccine Response Rate for Pre-F Specific Binding Antibodies Against RSV A and RSV B (Via Enzyme Immunoassay [EIA]) measure: Frequency of Pre-F Specific IFN-γ/IL-4 Secreting T cells (Via Enzyme-Linked Immunospot [ELISpot] Assay) measure: Frequency of Pre-F Specific CD4 and CD8 T Cells Expressing Activation Markers (Via Intracellular Cytokine Staining [ICS] Assay) measure: Percentage of Participants (Part 2, Aged 60 to 79 Years) With Solicited Local and Systemic Adverse Reactions Through 14 Days After Revaccination measure: Percentage of Participants (Part 2, Aged 60 to 79 Years) With Unsolicited AEs Through 28 Days After Revaccination measure: Percentage of Participants (Part 2, Aged 60 to 79 Years) With Any MAAEs Through 6 Months After Revaccination measure: Percentage of Participants (Part 2, Aged 60 to 79 Years) With Any SAEs, AESIs, and AEs Leading to Study Discontinuation Through 6 Months After Revaccination sex: ALL minimumAge: 18 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287437 id: B2023-335R briefTitle: HRS9531 Controls Weight Regain in Obese Subjects overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-01 date: 2025-06-30 date: 2025-12-31 date: 2024-03-01 date: 2024-03-01 name: Shanghai Zhongshan Hospital class: OTHER briefSummary: This is a single-center, double-blinded, randomized, placebo-controlled phase II study to explore the effectiveness, safety and energy balance mechanism of low-frequency continuous subcutaneous injection of HRS9531 to inhibit weight regain in obese non-diabetic and obese diabetic patients conditions: Obesity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 72 type: ESTIMATED name: HRS9531 name: HRS9531 placebo measure: Percent Change in Body Weight from 24 weeks measure: Energy intake change from 24 weeks measure: Energy expenditure change from 24 weeks measure: Metabolic adaptation from 24 weeks measure: Systolic blood pressure and diastolic blood pressure change from 24 weeks measure: Body fat rate change from 24 weeks measure: Serum total cholesterol change from 24 weeks measure: Triglyceride change from 24 weeks measure: Nonestesterified fatty acid change from 24 weeks measure: Energy intake at baseline measure: Energy expenditure at baseline measure: Appetite at baseline (assessed by Visual Analogue Scale subjective rating scale) measure: Percent Change in Body Weight at 24 weeks measure: Appetite at 24 weeks (assessed by Visual Analogue Scale subjective rating scale) measure: Energy expenditure at 24 weeks measure: Energy intake at 24 weeks measure: Change of body weight at 24 weeksl from baseline sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Xiaoying Li city: Shanghai country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06287424 id: HMO-2O-0536 briefTitle: The Efficacy Of AGE On Periodontitis overallStatus: COMPLETED date: 2021-04-04 date: 2022-09-30 date: 2023-01-01 date: 2024-03-01 date: 2024-03-01 name: Hadassah Medical Organization class: OTHER name: Wakunaga Pharmaceutical Co., Ltd. briefSummary: The objective of this study is to assess the long-term efficacy of "AGE among on deep periodontal pockets by different doses of "AGE" for a period of 18 months. conditions: Periodontitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 4 Regimen parralel groups primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Eligible subjects will be stratified based on Screening mean PPD (above or below 2mm), mean GBI (above or below 0.44), mean age (above or below 45 years old), gender (male or female) and tobacco use (yes or no). Within strata, subjects will be randomly assigned to one of the treatment groups using an encoded program. This assignment process and the distribution of test products will be conducted in a protected area that will ensure blinding of the examiner to the identity of the test products. whoMasked: PARTICIPANT count: 300 type: ACTUAL name: Aged Garlic Extract name: Placebo measure: Gingival Bleeding Index (GBI) measure: Probing Pocket Depth (PPD) sex: ALL minimumAge: 30 Years maximumAge: 60 Years stdAges: ADULT facility: Hebrew University city: Jerusalem zip: 9112102 country: Israel lat: 31.76904 lon: 35.21633 hasResults: False
nctId: NCT06287411 id: 202436 briefTitle: Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies overallStatus: RECRUITING date: 2023-12-01 date: 2025-12-31 date: 2025-12-31 date: 2024-03-01 date: 2024-03-05 name: Xiao Chen class: OTHER briefSummary: This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards. conditions: Hepatic Malignancies studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 36 type: ESTIMATED name: FAPI PET/MR combined with gadoxetate disodium measure: Diagnostic performance measure: Quantitative parameters of PET/MR sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Nuclear Medicine, Daping Hospital of Army Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400010 country: China name: Xiao Chen, Ph.D role: CONTACT phone: 15922970174 email: xiaochen229@foxmail.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06287398 id: NHL38 briefTitle: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-11 date: 2031-11 date: 2024-03-01 date: 2024-03-01 name: Australasian Leukaemia and Lymphoma Group class: OTHER briefSummary: The goal of this clinical trial is to evaluate clinical efficacy of incorporating Epcoritamab into the salvage treatment routine for relapsed-refractory aggressive B-cell lymphoma, followed by autologous stem-cell transplantation (ASCT) and consolidation Epcoritamab. The main questions it aims to answer are:
3. Consolidation treatment: consists of six 28-day cycles of subcutaneous Epcoritamab, commencing 6 - 12 weeks post ASCT. conditions: DLBCL - Diffuse Large B Cell Lymphoma conditions: High-grade B-cell Lymphoma conditions: High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements conditions: DLBCL, Nos Genetic Subtypes conditions: High Grade B-Cell Lymphoma, Not Otherwise Specified conditions: Follicular Large Cell Lymphoma, Relapsed conditions: Follicular Large Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 39 type: ESTIMATED name: Epcoritamab measure: Event-free survival (EFS) measure: Evaluate safety and tolerability of combination Epcoritamab with salvage-ASCT measure: Overall response rate (ORR) measure: Complete response rate (CRR) measure: Overall Survival (OS) measure: Progression free survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06287385 id: NELN202212A briefTitle: An Exploratory RWE Study Exploring Effects of a Goat Milk Based Young Child Formula on Health Benefits overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-05-15 date: 2025-12-15 date: 2024-03-01 date: 2024-03-01 name: Danone Nutricia class: INDUSTRY briefSummary: This is an exploratory real-world study designed to gain insight into the role of the product in terms of health benefits in toddlers, with the potential to generate hypotheses on key and other exploratory objectives. conditions: Healthy Children studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 120 type: ESTIMATED name: Goat-milk Based Formula measure: Stool characteristics measure: Gastrointestinal symptoms measure: Quality of life of subjects measure: Lifestyle-related immune indicators measure: Safety parameters sex: ALL minimumAge: 1 Year maximumAge: 2 Years stdAges: CHILD facility: Peking University Third Hospital city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False